Growing evidence supports the clinical benefits and anti-inflammatory effects of drugs targeting the NLRP3 inflammasome and IL-1β pathway in several diseases (61), but whether they are pregnancy-safe and effective in preeclampsia needs to be determined. The gene discussed is NLRP3; the disease is preeclampsia.